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Abstract
Background: WRAP53, including α, β and γ isoforms, plays an important role not only in the stability of p53 mRNA,
but also in the assembly and trafficking of the telomerase holoenzyme. It has been considered an oncogene and is
thought to promote the survival of cancer cells. The aim of this study was to detect the role of TCAB1 (except
WRAP53α) in the occurrence and development of head and neck carcinomas.
Methods: Immunohistochemistry was used to detect the TCAB1 expression in clinical specimen sections and
performed western blotting to check the TCAB1 expression levels in cell lines. TCAB1 was depleted using shRNA
lentivirus and the knockdown efficiency was assessed using q-PCR and Western blotting. We performed CCK-8
assays and flow cytometry to check the cell proliferation potential and used the trans-well assay to test the invasion
ability in vitro. Xenografts were used to detect the tumor formation potential in vivo. Moreover, we performed cDNA
microarray to investigate the candidate factors involved in this process.
Results: We observed a notable overexpression of TCAB1 in head and neck carcinoma clinical specimens as well
as in carcinoma cell lines. Knockdown of TCAB1 decreased the cellular proliferation potential and invasion ability
in vitro. cDNA microarray analysis suggested the possible involvement of several pathways and factors associated
with tumorigenesis and carcinoma development in the TCAB1-mediated regulation of cancers. Furthermore,
the xenograft assay confirmed that the depletion of TCAB1 would inhibit tumor formation in nude mice. The
immunohistochemistry results of the mice tumor tissue sections revealed that the cells in shTCAB1 xenografts
showed decreased proliferation potential and increased apoptotic trend, meanwhile, the angiogenesis was
inhibited in the smaller tumors form shTCAB1 cells.
Conclusions: Our study demonstrated that depletion of TCAB1 decreased cellular proliferation and invasion potential
both in vitro and in vivo. The data indicated that TCAB1 might facilitate the occurrence and development of head and
neck carcinomas. In future, TCAB1 might be useful as a prognostic biomarker or a potential target for the diagnosis and
therapy of head and neck carcinomas.
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Background
Telomerase is a ribonucleoprotein (RNP) containing RNA
and proteins, and was first discovered in 1985 in the ciliate
Tetrahymena cell by Greider and Blackburn [1]. Most
human tumor cells, about 85%-90%, utilize the telome-
rase holoenzyme to maintain telomere length by adding
TTAGGG repeats to telomere ends [2]. In the last 10 years
of 20th century, several labs had investigated the telome-
rase activity in head and neck tumors. In normal oral
mucosa, the frequency of telomerase positive cells was as
low as 0%-5%, while approximately 50% and 85%-100% of
cells were telomerase positive in premalignant tissues and
in malignant head and neck squamous cell carcinoma,
respectively [2-9]. Even though previous reports indicated
that telomerase played an indispensable role in tumori-
genesis and development of head and neck tumors, the
detailed underlying mechanism is still poorly understood.
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Telomerase Cajal body protein 1(TCAB1), accumulated
in Cajal bodies, is seen as a factor associated with dys-
kerin, which plays a core role in the assembly and stability
of telomerase. Further, TCAB1 was verified to be involved
in telomerase holoenzyme assembly and in driving
telomerase to Cajal body [10,11]. Although a subsequent
study indicated that telomerase could recruit TCAB1 and
Cajal body independently [12], TCAB1 was regarded as an
essential component of the telomerase holoenzyme. Since
the localization of telomerase to Cajal body was regarded
a crucial step in the telomerase holoenzyme assembly in
telomerase positive tumors, mutation of TCAB1 gene
could result in disorders as dyskeratosis congenita associ-
ated with telomeres shortening, which partly caused aging
senescence or cancer [13,14]. Thus, it is evident that TCAB1
might be an oncogene which to a certain extend could
facilitate tumorigenesis and tumor development.
Although the involvement of TCAB1 in telomere
maintenance was uncovered only recently in 2009 [10],
TCAB1 itself is not a newly discovered protein, and was
well known prior to this as WRAP53 or WDR79.
WRAP53 could transcribe several different isoforms, as
WRAP53α, β, or γ, and the previous studies demonstrated
that only the WRAP53α was identified as a natural anti-
sense transcript of p53, which regulates p53 protein levels
by targeting the 5’- untranslated region of p53 mRNA
[15]. So here we used TCAB1 to represent the WRAP53
isoforms except α. Previously reported data in vitro
suggested that overexpression of WRAP53 could induce
cellular transformation while WRAP53 knockdown by
exogenous siRNA on the other hand, could induce cellu-
lar apoptosis [16], also indicating potential oncogenic
characteristics of TCAB1. Head and neck carcinoma is
approximately the sixth most common cancer among
global cancers [17,18], and the five year survival rate
has remained at about 50% in the past decades [19]. These
cancers are indeed harmful to humans, but to date, there
are no specific studies on the functional relevance of
TCAB1 in head and neck tumors.
Our findings showed that TCAB1 (except WRAP53α)
was overexpressed in human head and neck carcinoma cell
lines, including human nasopharyngeal carcinoma (NPC)
cell line CNE1, oral squamous carcinoma cell (OSCC) lines
HSC-3, Cal-27, and adenoid cystic carcinoma (ACC) cell
line ACC2. Meanwhile, TCAB1 was overexpressed in
most (~80%) specimens from nasopharyngeal carcinoma
patients compared to the nasopharyngitis patients, while
was expressed at low levels in human primary normal oral
cells, human periodontal ligament cells (PDLC) and dental
pulp cells (DPC) (P < 0.05). Further studies showed that
knockdown of TCAB1 by exogenous shRNA using lenti-
virus reduced the proliferation potential of human OSCC
cell lines Cal-27, HSC-3 and ACC cell line ACC2 in vitro,
and the cells treated with shTCAB1 lentivirus generated
smaller tumors in nude mice. Moreover, we performed
immunohistochemistry (IHC) of the xenografts tumor
sections from shTCAB1 treated OSCC cells compared to
the shScrambled cells. The data showed that the proli-
feration markers, both the Ki-67 and PCNA, were lower
expressed while the apoptotic markers were upper regu-
lated, which suggested depletion of TCAB1 could also
inhibit the growth of cancer cells in vivo. The cDNA
microarray data indicated that the p53 signaling path-
way, cell cycle and apoptosis pathway, Jak-STAT signaling
pathway and several others, might be involved in this
TCAB1-mediated tumor regulation process. All of our
studies imply that TCAB1 is potential target for diagnosis
of and molecular therapy for head and neck cancers.
Materials and methods
Clinical specimens
A total of seventy paraformaldehyde-fixed paraffin-embedded
tissues with histopathology reports were collected in order
to detect TCAB1 expression. Among these, fifty were
NPC tissues and twenty were nasopharyngitis (NPi)
tissues. All seventy tissue specimens were procured from
the Sichuan Province Tumor Hospital from 2010 to 2012
(NPC: 2011–2012, NPi: 2010–2012). The study was
carried out under the approval and supervision of the
Ethics Committee of Sichuan University and written
informed consents were obtained from each patient.
Cell lines and cell culture
Two OSCC cell lines, HSC-3, Cal-27, one NPC cell line
CNE1, and one ACC cell line ACC2 were used in this study.
HSC-3, Cal-27, and ACC2 were cultured in Dulbecco’s
modified Eagle’s medium (DMEM, HyClone) supple-
mented with 10% fetal bovine serum (FBS, HyClone) and
penicillin-streptomycin (Thermo Scientific). CNE1 was
cultured in RPMI-1640 (HyClone) with 10% fetal bovine
serum and penicilin/streptomycin. All of the cell lines
were obtained from state key laboratory of oral diseases,
and HSC-3 (JCRB0623) was purchased from the cell bank
of Japanese Collection of Research Bioresource (JCRB,
Shinjuku, Japan). Primary periodontal ligament cells (PDLC)
and human dental pulp cells (hDPCs) were isolated from
clinical fresh specimens and cultured in DMEM with 10%
fetal bovine serum and penicillin-streptomycin. All cells
were cultured in a humidified incubator at 37°C with
5% CO2.
Immunohistochemistry
Pathological specimens were analyzed by routine immuno-
histochemical methods [20,21]. In brief, 4 μm formalin-fixed
and paraffin-embedded (FFPE) sections were de-paraffinized
with xylene twice and rehydrated in graded 100%, 90%,
80%, 70% alcohol solution, and antigens were retrieved
with Tris-EDTA buffer for 3-5 min at 100°C. The slides
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were peroxidase blocked with 3% hydrogen peroxide solu-
tion for 10 min and then blocked using 5% bovine serum
albumin (Sigma) for 30 minutes. Slides were subsequently
incubated with primary antibody against TCAB1 (Novus,
1:200), VEGF (Santa cruz biotechnology, 1:100), Bcl-2
(Santa cruz biotechnology, 1:150), Caspase 3 (Santa cruz
biotechnology, 1:150), Ki-67 (Abcam, 1:150), PCNA (Cell
Signaling Technology, 1:100), CD34 (Abcam, 1:25) for 2 h
at 37°C or overnight at 4°C and detected with ChemMate™
EnVision kit (DAKO). The slides were counterstained
with haematoxylin, dehydrated with graded alcohol and
mounted. Each time for IHC, a section slide was used as
negative control, of which the only difference was incu-
bated without primary antibody. Finally, scanned the slides
and scored the data with imageScope software (Aperio).
Lentivirus assembly and infection
The shTCAB1-A ~D lentivirus was constructed and
assembled by ShangHai SBO Medical Biotechnology Co.
and infected cells with polybrene (5 μg/mL, Millipore).
Four different shTCAB1 lentivirus products were used, and
labeled shTCAB1-A ~D (TCAB1, NM_018081.2, A ~D:
site 645–663,708-726,1452-1470 and 1738–1756, re-
spectively). Another shTCAB1-667 lentivirus was assem-
bled using pCMV-dR8.2 dvpr (Addgene), pCMV-V-SVG
(Addgene) and shTCAB1-667 (shRNA, targeting CACC
CAACCTGAGAACTTCTT, Sigma Aldrich). The cells
infected with lentivirus were selected using puromycin
(Thermo). Meanwhile, the shScramble lentivirus (shScra)
was used as negative control.
Western blotting
Cells were trypsinized using 0.025% trypsine-EDTA (Gibco)
and collected by centrifugation. Total proteins were isolated
using the Radio Immunoprecipitation Assay buffer (RIPA
lysis buffer, Beyotime), and western blotting was per-
formed using the routine approach. Primary TCAB1 anti-
body (Novus) was diluted at 1:2000 in 5% BSA and GAPDH
(1:5000, Trevigen) was used as an internal control.
Quantitative real-time PCR
The cells were collected using 0.025% trypsine-EDTA
and the total RNA was extracted with TRIzol regent
(Life Technologies). Reverse transcription PCR was
performed using Primescript RT reagent Kit (TaKaRa),
and further quantitative real-time PCR analysis was
performed using SYBR select master mix (Applied
Biosystems; TCAB1 primers: Forward, 5’-CATATCT
GGGACGCATTCACT-3’, Reverse, 5’-GTTGAAGCCA
CAGAAGAGCTG-3’). The PCR results were quan-
tified using semi-quantitative method as previously
reported [22].
Cell proliferation and cell cycle assay
The cells were seeded in 96-well plates at a density of 103
per well and Cell Counting Kit-8 assay (CCK-8, Dojindo)
was performed to check the proliferation potential. Dupli-
cates sets of 4 wells each were assessed for each time
point. After every 24 h post seeding, the absorbance was
measured at 450 nm using Thermo Scientific Varioskan
Flash (Thermo Scientific).
Cells were collected and washed with PBS, fixed with
70% cold ethanol at 4°C for 2 h, and passed through 70 μm
Falcon (BD Biosciences) to obtain a mono-dispersed cell
suspension. The mono-dispersed cells were incubated
with RNase A at 37°C for 30 min and stained with pripi-
dium iodide (PI) at 4°C for 30 min (Cell Cycle Detection
Kit, KeyGEN). Cell cycle assay was performed in a flow
cytometer (Beckman).
Cell invasion assay
The matrigel (BD Biosciences) was diluted with serum-
free DMEM at 1:5, and added carefully to the bottom of
the trans-well insert (8 μm, BD Biosciences) placed in a
24-well plate without any bubbles. For every group, trip-
licate were maintained. The trans-well inserts were incu-
bated at 37°C at least 1 h before seeding cells. Cells were
detached using 0.025% trypsin-EDTA and washed with
PBS, centrifuged and resuspended in serum free DMEM.
For each group, 5 × 104 cells were seeded in every trans-
well insert, and DMEM supplied with 10% FBS was
added in every well of the 24-well plate. After culturing
for 24 or 48 h, the cells that adhered in the inserts were
carefully wiped and fixed with 70% methanol, and stained
with haematoxylin.
cDNA microarray
Cells from shScramble and shTCAB1 groups were prepared
simultaneously, and the cDNA microarray assay was done
by Invitrogen Co. (Invitrogen, Shanghai, OS130121002,
GSE54224). The assays were performed on the platform
of Affymetrix GeneChip Human Gene 1.0 ST Array. The
raw data was normalized and further analyzed after log
transformation of the fold changes (log 2). The expression
level of each gene was compared between the shTCAB1
and shScra groups, and a change of 1.3-folds was set as a
threshold to identify differences in gene expression. Fi-
nally, we analyzed all of the selected genes with Kyoto
Encyclopedia of Genes and Genomes (KEGG) to identify
the pathways. The detailed ontology results are shown in
Table 1.
Animal study and xenografts tumor formation assay
Four-week-old female BALB/c nu/nu mice were purchased
from the laboratory animal center of Sichuan University
and maintained in the animal facility. All experimental
procedures involving animals were done in compliance
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with institutional and governmental requirements, and ap-
proved by the laboratory animal center’s Animal Care and
Use Committee. Cells were collected and re-suspended in
DMEM. A cell density of 5 × 106 cells from each group in
200 μl DMEM were injected subcutaneously into the left
and right neck of the BALB/c nude mice respectively. The
tumor growth curves were determined by measuring the
tumor size using vernier caliper, and tumor volumes were
calculated by the formula l*w*h/2 (mm3). All mice were
mercifully killed at day 27 and the tumors were removed
and weighed. Tumors tissues were washed with PBS and
fixed with 4% paraformaldehyde for IHC studies.
TUNEL assay
The 4 μm FFPE xenografts sections were pre-treated as
IHC procedures to remove paraffin and rehydrate. In brief,
fixed the slides in 4% formaldehyde in PBS for 15 minutes
after washing, and permeabilize the slides with 20 μg/ml
Proteinase K solution (Promega) for 10 min at room
temperature. Wash and fix again. Then equilibrate with
equilibration buffer (promega) for 10 minutes at room
temperature, and label the slides with TdT reaction
mix (promega) for 1 h at 37°C in a humidified chamber.
Stop reaction with 2X SSC and wash, counterstain use
Vectashield Mounting Medium with DAPI (Vector labs).
Statistical analysis
Statistical Package for Social Science (SPSS) version 19.0
for windows and GraphPad Prism 6 were used to
analyze the data. Student’s t test was used to compare
the data between every two groups respectively. For all
statistical analysis, P value less than 0.05 was considered
statistically significant.
Results
TCAB1 is overexpressed in human head and neck
carcinomas cell lines
To investigate whether TCAB1 exhibits oncogenic cha-
racteristics in human head and neck carcinomas, we
checked the protein expression level of TCAB1 in se-
veral human head and neck carcinoma cell lines and two
normal primary cells. The results indicated that TCAB1
was significantly overexpressed in NPC cell line CNE1,
OSCC cell lines HSC-3 and Cal-27, and also in ACC cell
line ACC2, while the expression level was relatively low
in human primary normal cells, including human peri-
odontal ligament cells (PDLC) and human dental pulp
cells (DPC) (Figure 1a, b). Furthermore, we performed
immunohistochemistry (IHC) experiments with 50 hu-
man NPC specimens and 20 human nasopharyngitis
(NPi) specimens. The results revealed that TCAB1 was
overexpressed in approximate 80% NPC biopsies (40 out
of 50 samples), but only in 15% of NPi biopsies (3 out of
20 samples) (Figure 1c, d). These data demonstrate that
TCAB1 is overexpressed in human head and neck
carcinomas, which suggests that TCAB1 may play an
important role in head and neck cells tumorigenesis.
The previous studies revealed that TCAB1 overexpres-
sion might correlated with poor prognosis in head and
neck cancers [16]. Although the samples of NPC
patients were collected from 2011 to 2012, and most of
them are less than 3 years, we still would like to investi-
gate the correlation between TCAB1 overexpression and
patient survival. Because of the time, we can’t do the
3 years survival curve, but we calculated the Median
Survival Time based on our clinical follow-up survey. In
all of the 50 NPC patients, 5 of them were dead up to
now. The follow-up survey data showed that the median
survival time is 27 months and the 95% confidence
interval is 16.265-37.735.
TCAB1 facilitates proliferation in head and neck
carcinoma cell lines
Endogenous TCAB1 in OSCC cell lines Cal-27, HSC-3
and ACC cell line ACC2 was depleted using lentivirus
carrying shTCAB1 plasmids. Quantitative PCR results
show that TCAB1 decreased efficiently upon infection
with lentivirus containing 5 different shTCAB1 sequences.
Table 1 KEGG analysis results
hsa05200: Pathways in cancer (42) AKT3, APC, APPL1, BIRC2, BIRC7, BMP2, CDC42, CDK6, CEBPA, CHUK, CUL2, DAPK1, DCC, E2F3, FAS, FGF17,
FGF22, FGF6, FGF9, FLT3, FZD10, FZD3, GLI1, HGF, KITLG, KRAS, MAPK8, MECOM, PDGFRB, PIAS2, PIK3CB,
PIK3CG, PLD1, PTGS2, RAF1, RXRG, SHH, SMAD4, SOS1, SPI1, WNT1, WNT5B
hsa04115: p53 signaling pathway (18) ATM, ATR, BBC3, CCNB1, CCNB2, CCND2, CDK1, CDK6, FAS, GADD45A, GADD45B, IGFBP3, MDM4, SERPINE1,
SESN1, SESN3, TP53AIP1, ZMAT3
hsa04110: Cell cycle (20) ANAPC4, ATM, ATR, CCNB1, CCNB2, CCND2, CDC23, CDK1, CDK6, CDKN2D, E2F3, E2F5, GADD45A,
GADD45B, ORC2, ORC4, ORC5, SMAD4, STAG1, TTK
hsa04210: Apoptosis (15) AIFM1, AKT3, ATM, BIRC2, BIRC7, CASP6, CHUK, FAS, IRAK3, IRAK4, NGF, PIK3CB, PIK3CG, PPP3CB, PRKACG
hsa04151: PI3K-Akt signaling
pathway (40)
AKT3, CCND2, CDK6, CHUK, COL11A1, COL11A2, COL3A1, COL5A3, CREB3L1, CSF3, FGF17, FGF22, FGF6,
FGF9, FOXO3, GNGT1, HGF, IFNA13, IFNAR1, ITGB7, JAK2, JAK3, KITLG, KRAS, NGF, NOS3, NR4A1, PCK1,
PDGFRB, PIK3CB, PIK3CG, PKN2, PPP2R2A, PPP2R3A, PPP2R3C, PPP2R5A, RAF1, SOS1, TCL1B, THBS4
hsa04630: Jak-STAT signaling
pathway (29)
AKT3, CCND2, CISH, CRLF2, CSF3, IFNA13, IFNAR1, IFNW1, IL10RB, IL11RA, IL12B, IL12RB1, IL13RA1, IL20,
IL6ST, JAK2, JAK3, LIF, LIFR, PIAS2, PIK3CB, PIK3CG, PIM1, SOCS1, SOCS4, SOS1, SPRED1, SPRED3, STAM2
Differently expressed genes (≥1.3-fold change) between the shTCAB1 and shScra groups.
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It was also notable that the shRNA containing scramble
sequence (shScra) had no effect as compared to the high
knockdown efficiency of shTCAB1 (Figure 2a). Moreover,
the western blot results indicated that TCAB1 drastically
decreased in cells treated with shTCAB1 lentivirus
(Figure 2b). The cells proliferation assay results demon-
strated that cells treated with shTCAB1 lentivirus exhi-
bited lower proliferation potential than the wildtype and
shScra cells (Figure 2c), which is consistent with the
previous study [16]. To avoid the experimental error, we
repeated the CCK-8 assay at least twice independently
and used different shRNAs and cell lines. Our studies
display that TCAB1 is required for cells proliferation
in vitro, and reduction of TCAB1 expression using
exogenous shRNA leads to a corresponding decrease in
their proliferation potential.
Depletion of TCAB1 might induce cell cycle arrest
The data from CCK-8 assay showed that depletion of
TCAB1 in Cal-27 reduced its proliferation potential. To
verify this, we performed Fluorescence Activated Cell
Sorter (FACS) experiment. The results also indicated that
the cells treated with shTCAB1 lentivirus in S phase were
sufficiently lesser than shScramble cells (Figure 2d).
Although the underlying mechanism is still not under-
stood, the study suggests that knockdown of TCAB1
in vitro influences the proliferation of OSCC cells.
TCAB1 might influence invasion abilities of head and
neck carcinoma cells in vitro
Invasion is one of important indicators of malignant
tumors, and therefore, we explored whether TCAB1 is
involves in cell migration process. Using the OSCC cell
Figure 1 TCAB1 was overexpressed in cell lines and in tissues of head and neck cancers. a. Protein level of TCAB1 in head and neck
cancer cell lines (the first 4 samples) compared to human normal primary cells (the last 2 samples). b. Quantitative results of the TCAB1 protein
levels relative to GAPDH in each cell line. c. The typical IHC results (Left: TCAB1 positive, Right: TCAB1 negative) of TCAB1 in human NPC and NPi.
d. Percentage of TCAB1 positive specimens of NPC and NPi in each group. Three different persons estimated the 70 specimens independently,
the TCAB1 negative or week expressed specimens were thought as negative here. Statistical analysis was determined by Student’s t test (***P < 0.005).
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lines Cal-27, HSC-3, and ACC cell line ACC2 treated
with shTCAB1 lentivirus, we tested the migration poten-
tial using matrigel-based trans-well experiments. The
data indicated that knockdown of TCAB1 in Cal-27,
ACC2 and HSC-3 significantly reduced the migration
potential compared to negative control cells, the
wildtype cells and shScra cells (Figure 3). Our studies
suggest that TCAB1 indeed influence and facilitate head
and neck carcinoma cells invasion in vitro.
The oncogenic potential of TCAB1 may influence many
pathways associated with cancer
To uncover which pathways were involved in TCAB1-
mediated cancer regulation processes, we performed
cDNA microarray analysis in an effort to identify some
candidate pathways or factors. By comparing the expres-
sion level of genes between Cal-27 cells with and with-
out shTCAB1 lentivirus infection, we selected thousands
of differentially expressed genes (a 1.3-folds change was
set as thresholds). Using KEGG pathway analysis tool
online, we analyzed all the genes showing differences in ex-
pression, and the results showed that the TCAB1-regulated
genes were involved in many pathways associated with
cancers (Table 1). This included the p53 signaling pathway,
the PI3K-AKT signaling pathway, the cell cycle and apop-
tosis pathway, Jak-STAT signaling pathway and so on. Here,
we list the genes involved in Table 1. These studies reveal
that TCAB1 may influence many cellular processes and
pathways in cancer, but identification and confirmation of
the exact pathway or factors is extremely difficult from the
current microarray data.
TCAB1 promotes tumor growth in vivo
To further evaluate the oncogenic potential of TCAB1
in vivo, xenograft experiments were established in nude
mice using OSCC Cal-27 cells with and without TCAB1
knockdown. The volume of tumors was tested every
4 days from the 11th day when the tumors were tangible,
Figure 2 Depletion of TCAB1 reduced the cell proliferation in vitro. a. qPCR results. Using exogenous shTCAB1 lentivirus (4 different shRNA
targets) depleted TCAB1 mRNA significantly. b. Protein level also significantly decreased after shTCAB1 lentivirus treatment. c. Depletion of TCAB1
by exogenous shRNA decreased cell proliferation in Cal-27, ACC2 and HSC-3 cells. d. FACS results. Depletion of TCAB1 might facilitate cancer cell
arrest, and shTCAB1-treated cells are significantly less in S phase. Statistical analysis was determined by Student’s t test (**P < 0.01, ***P < 0.005).
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and the data showed that the tumors generated from
cells with TCAB1 knockdown grew slower compared to
the scramble control (Figure 4a). Both the volume and
the weight of the tumors were significantly less, which
might result of the cells with TCAB1 knockdown had lower
proliferation or growth potential compared to the shScra
cells (Figure 4b). Fixed the xenografts tumor with formalin
and embedded with paraffin, we performed IHC to check
the TCAB1 expression of xenografts in vivo. The results
showed the smaller generated tumors from shTCAB1-C
cells expressed less TCAB1 relative to xenografts generated
from shScra cells (Figure 4c).
The decreased proliferation potential and increased
apoptotic trend of shTCAB1 cells result in forming smaller
xenografts tumor in vivo
In addition, we utilized the FFPE xenografts sections to
investigate the reason of smaller tumors generated by
shTCAB1-C cells in vivo. Firstly, we detected the expres-
sion of Ki-67 and PCNA, and the results indicated that
the xenografts sections of shTCAB1-C cells expressed
less than the other (Figure 5a, b), which suggested that
the shTCAB1-C cells proliferation potential was also
decreased in vivo. Meanwhile, we tested the apoptotic
trend of cells with or without depletion of TCAB1 in vivo
by some protein markers, like Caspase 3, Bcl-2, and
TUNEL assay. The results indicated that in shTCAB1-C
cells, the xenografts sections showed lower expressed Bcl-
2 and upper expressed Caspase 3 (Figure 5c), which was
consistent with the previous studies [16] and implied that
the cells with TCAB1 depletion possessed higher apop-
totic trend, resulting in more apoptosis cells. Otherwise,
the TUNEL assay results also verified that sections from
cells with TCAB1 depletion had more DNA fragmenta-
tions resulting of apoptotic signaling cascades (Figure 5d).
Therefore, our data suggested that the decreased prolifera-
tion potential and the increased apoptotic trend might
induce the cells growth much slower, resulting in gene-
rating smaller xenografts tumor in vivo finally.
Besides, we wanted to know if the angiogenesis was
influenced or influenced the tumor formation in the
process. So we still performed IHC of VEGF and CD34
Figure 3 Depletion of TCAB1 resulted in decreased cell invasion potential. a. Depletion of TCAB1 in Cal-27, ACC2 and HSC-3 cells caused
less cells invading through the micropores by trans-well test. b. Statistical analysis of the invaded cells, which was determined by Student’s t test
(**P < 0.01, ***P < 0.005).
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to check the micro-vessels generation in the xeno-
grafts. The results indicated that the sections from
shTCAB1-C cells exhibited less VEGF expression in cyto-
plasm (Figure 6a). Otherwise, the micro-vessels displayed
by CD34 signaling indicated that the more micro-vessels
was necessary for supporting and supplying the bigger
xenografts tumor formation (Figure 6b).
Discussion
TCAB1, also known as WRAP53 isoforms β and γ, was
involved in telomerase holoenzyme assembly and traf-
ficking while the isoform WRAP53α was known as a
natural antisense transcript that regulated p53 mRNA
levels [10,11,15,23]. p53 is a very important suppressor
gene in tumorigenesis as we all know, and a mutation in
p53 may result in tumorigenesis. Furthermore, telome-
rase extends telomeres in most tumors, which assisted
the prevention of senescence or apoptosis. Interestingly,
WRAP53 plays important roles not only in stability of
p53 mRNA, but also in telomerase holoenzyme assem-
bly. These suggested that WRAP53 may have an effec-
tive role in two essential human tumorigenesis
processes, namely the p53 pathway and the telomerase
activity. All previously reported studies demonstrated
that WRAP53 might be a major target molecule in can-
cer research, with possible functional relevance in head
Figure 4 TCAB1 knockdown inhibits tumor growth in vivo. a. shTCAB1-C and shScra cells were injected subcutaneously into the left and right
neck of the nude mice respectively. Measured the tumors size from the 11th day using vernier caliper and calculated the volume of tumors by
formula l*w*h/2 (mm3). Finally, got out the xenografts carefully after mercifully killed the mice. b. Measured the final volume and weighted the
final weight of the removed tumors. c. Performed IHC against TCAB1 using mice xenografts sections. The smaller tumors expressed less TCAB1
compared to shScra cells. Statistical analysis of the IHC data used Aperio ImageScope software and all of the data were determined by Student’s
t test (*P < 0.05, **P < 0.01, ***P < 0.005).
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and neck carcinomas. In fact, WRAP53 itself has been
the focus of investigation for many scientists. The fol-
lowing studies indicated that WRAP53 promoted cancer
cell survival and depletion of WRAP53 using exogenous
shRNA induces apoptosis in vitro [16], and also
WRAP53 is necessary to form Cajal bodies and can dir-
ect the survival of motor neuron complex to Cajal bod-
ies [24]. Cajal bodies were identified more than a
century ago, and were seen as the site of initial modifica-
tion and assembly of several U snRNPs [25,26]. While the
function of WRAP53 based on Cajal body has been studied
extensively, the mechanism of WRAP53 in tumorigenesis
has also attracted much attention. Recently, Rao et al.
demonstrated that WRAP53 was overexpressed in Esopha-
geal Squamous Cell Carcinoma (ESCC) tissues compared
to the adjacent non-neoplastic tissues [27]. However,
there are so less and unclear studies on the functional
significance of WRAP53 in head and neck cancers
research thus far, and it would be interesting and
beneficial to combine the knowledge on WRAP53 from
previous studies and explore the possibility of its clinical
application in head and neck cancers.
In our study here, we focused on the function of TCAB1,
the WRAP53 isoforms except α, in tumorigenesis and
development of head and neck carcinomas, so we used the
symbol TCAB1 here but WRAP53.
Figure 5 Decreased proliferation potential and increased apoptotic trend due to depletion of TCAB1 resulted in smaller xenografts
tumor in vivo. a. Performed IHC against proliferation markers Ki-67 and PCNA using mice xenografts section, and the sections from shTCAB1 cells
displayed lower expressed Ki-67 and PCNA. b. Statistical analysis of the Ki-67 and PCNA using Aperio ImageScope software. c. Apoptotic markers
Caspase 3 and Bcl-2 were performed using IHC on mice xenografts sections. In xenografts derived from shTCAB1 cells, the results showed
up-regulated Caspase 3 and down-regulated Bcl-2, the statistical analysis data were not shown here. d. TUNEL assay. Analyse the apoptosis of
xenografts sections using TUNEL assay. Results indicated apoptosis was significantly increased in shTCAB1 cells. Statistical analysis of the data were
determined by Student’s t test (*P < 0.05, **P < 0.01, ***P < 0.005).
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Our studies showed that TCAB1 was overexpressed in
three different head and neck cancer cell lines, including
NPC, OSCC and ACC, as well as the clinical patient speci-
mens sections detected by IHC. Depletion of TCAB1 using
shRNA lentivirus can reduce the growth rate not only
in vitro, which is consistent with previous study [16], but
also in vivo. The results of CCK-8 assay exhibited the pro-
liferation potential was significantly decreased in TCAB1
knockdown cells. Besides, the FACS data showed cells
treated with shTCAB1 lentivirus were arrested in cell cycle,
while the cells in S phase were significantly less than the
shScramble cells, which meant that DNA replication
in shTCAB1 cells was slower than in the control cells.
All of these indicated that TCAB1 promotes cancer
cell proliferation and a depletion of endogenous TCAB1
by exogenous shRNA reduces tumor growth rate in vitro.
Furthermore, invasion is a very important parameter for
malignant tumors. Hence, we performed an invasion test
in vitro using trans-well experiments, and our results
showed that depletion of TCAB1 reduced the invasion
potential of head and neck cancer cells. It would be very
interesting to study how TCAB1 facilitates cancer cells
invasion in future.
Based on the proliferation and invasion test in vitro, we
attempt to investigate the mechanism implicated in the
process using cDNA microarray, which was performed on
the platform of Affymetrix GeneChip Human Gene 1.0
ST Array. Almost thirty thousand genes’ transcription
Figure 6 The angiogenesis was inhibited in shTCAB1 xenografts. a. IHC against VEGF was performed using mice xenografts sections.
Statistical analysis of the VEGF expression used Aperio ImageScope software. Data showed the xenografts derived from shTCAB1 expressed less
VEGF in cytoplasm. b. Performed IHC against CD34 using mice xenografts section. The results indicated xenografts from shTCAB1 displayed
significantly less micro-vessels. Statistical analysis of the data were determined by Student’s t test (***P < 0.005).
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were tested in this assay. By comparing the expression
level of every gene from two groups respectively, and
setting 1.3-fold change as threshold, we indentified
approximately 3.3 thousand differentially expressed genes.
All of the differently expressed genes were analyzed online
with Kyoto Encyclopedia of Genes and Genomes (KEGG)
database to obtain the pathway maps [28]. The pathway
distribution showed that several pathways associated with
cancers were implicated in this process, just like the p53
pathway, cell cycle, apoptosis pathway and so on (detail in
Table 1). Our data displayed that depletion of TCAB1
would affect the survival status of cancer cells, influence
the proliferation and apoptosis. Therefore, the involve-
ment of these pathways was not surprising at all. However,
the cDNA microarray was performed to explore some
candidate pathways or proteins which were regulated or
mediated by TCAB1 or WRAP53. For instance, given p53
is an important cancer suppressor, the p53 pathway might
by triggered by knockdown of TCAB1. The microarray data
indicated many factors were up-regulated, including
ATM, ATR, CDK1, CDK6, CCNB1, CCNB2, MDM4,
SESN1, SESN3, ZMAT3, and FAS, while some genes were
down-regulated, including GADD45A, GADD45B, CCND2,
BBC3, IGFBP3, SERPINE1, and TP53AIP1. These data
might give a direction for the further research. How-
ever, the current data are not sufficient to support an
in-depth hypothesis. Depletion of TCAB1 might trigger
many pathways directly or the changed cellular status
might trigger these pathways indirectly. This needs further
researches.
Xenografts assay in nude mice is very important for
verifying the function of a protein in tumorigenesis or
development. Our studies of the xenografts indicated
that the shTCAB1 cells would form much smaller
tumors in vivo. And through detecting many prolifera-
tion and apoptosis markers by IHC using the xenografts
sections, we could find that the smaller xenografts
tumor derived from shTCAB1 cells resulted of decreased
proliferation potential and increased apoptotic trend.
The data in vivo is consistent with the studies in vitro,
which is very important to the further investigation for
the diagnosis or therapy.
Angiogenesis is a critical event in tumor growth in vivo.
Vascular endothelial growth factor (VEGF) plays a core
role in angiogenesis, and its function has been verified in
head and neck cancers [29,30]. Our data from the IHC of
xenografts exhibited that VEGF was lower expressed in
sections derived from shTCAB1cells. However, only the
down-regulated VEGF is not sufficient. CD34 is a marker
for micro-vessels, and the abundant vessels are necessary
for supplying the tumor growth. In our study, the smaller
tumors sections derived from shTCAB1 cells displayed
much less micro-vessels, and which may limit the growth
of xenografts tumor in vivo.
In the future, we will focus on the detail mechanism of
the TCAB1/WRAP53-mediated function in head and
neck cancers. The data generated from in vitro and
in vivo here give us a future direction. Moreover, our
studies and others previous studies encourage us for the
future investigation.
Conclusions
In this study, the data showed that TCAB1 was over-
expressed in clinical specimens as well as in carcinoma
cell lines. Depletion of TCAB1 using shRNA lentivirus
inhibits cell proliferation and invasion in vitro. More
importantly, TCAB1 knockdown reduces the growth of
tumors in vivo. Given the oncogenic feature of TCAB1
genes, it should be an interesting potential target as a
clinical diagnostic biomarker and might be beneficial as a
future therapeutic target for head and neck carcinomas.
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